Tags

Type your tag names separated by a space and hit enter

Prognostic value of the human kallikrein gene 15 expression in ovarian cancer.
J Clin Oncol. 2003 Aug 15; 21(16):3119-26.JC

Abstract

PURPOSE

KLK15 is a newly cloned human kallikrein gene. Many kallikreins were found to be differentially expressed in ovarian cancer. Like other kallikreins, KLK15 is regulated by steroid hormones in cancer cell lines. KLK15 is upregulated mainly by androgens and to a lesser extent by progestins. The purpose of this study was to examine the prognostic value of KLK15 in ovarian cancer tissues.

MATERIALS AND METHODS

We studied KLK15 expression by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in 168 consecutive patients with epithelial ovarian cancer. Ten patients with benign ovarian tumors were also included in the study. An optimal cutoff point equal to the 50th percentile was defined based on the ability of KLK15 to predict progression-free survival and overall survival of the study population.

RESULTS

KLK15 expression levels were significantly higher in cancerous tissues compared with benign tumors. Kaplan-Meier survival curves showed that KLK15 overexpression is a significant predictor of reduced progression-free survival (PFS; P <.001) and overall survival (OS; P <.009). Univariate and multivariate analyses indicate that KLK15 is an independent prognostic factor for PFS and OS. A weak positive correlation was found between KLK15 expression and serum CA-125 levels.

CONCLUSION

KLK15 expression, as assessed by quantitative RT-PCR, is an independent marker of unfavorable prognosis for ovarian cancer.

Authors+Show Affiliations

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12915603

Citation

Yousef, George M., et al. "Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 21, no. 16, 2003, pp. 3119-26.
Yousef GM, Scorilas A, Katsaros D, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol. 2003;21(16):3119-26.
Yousef, G. M., Scorilas, A., Katsaros, D., Fracchioli, S., Iskander, L., Borgono, C., Rigault de la Longrais, I. A., Puopolo, M., Massobrio, M., & Diamandis, E. P. (2003). Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 21(16), 3119-26.
Yousef GM, et al. Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer. J Clin Oncol. 2003 Aug 15;21(16):3119-26. PubMed PMID: 12915603.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. AU - Yousef,George M, AU - Scorilas,Andreas, AU - Katsaros,Dionyssios, AU - Fracchioli,Stefano, AU - Iskander,Lisa, AU - Borgono,Carla, AU - Rigault de la Longrais,Irene A, AU - Puopolo,Manuela, AU - Massobrio,Marco, AU - Diamandis,Eleftherios P, PY - 2003/8/14/pubmed PY - 2003/9/16/medline PY - 2003/8/14/entrez SP - 3119 EP - 26 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 21 IS - 16 N2 - PURPOSE: KLK15 is a newly cloned human kallikrein gene. Many kallikreins were found to be differentially expressed in ovarian cancer. Like other kallikreins, KLK15 is regulated by steroid hormones in cancer cell lines. KLK15 is upregulated mainly by androgens and to a lesser extent by progestins. The purpose of this study was to examine the prognostic value of KLK15 in ovarian cancer tissues. MATERIALS AND METHODS: We studied KLK15 expression by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in 168 consecutive patients with epithelial ovarian cancer. Ten patients with benign ovarian tumors were also included in the study. An optimal cutoff point equal to the 50th percentile was defined based on the ability of KLK15 to predict progression-free survival and overall survival of the study population. RESULTS: KLK15 expression levels were significantly higher in cancerous tissues compared with benign tumors. Kaplan-Meier survival curves showed that KLK15 overexpression is a significant predictor of reduced progression-free survival (PFS; P <.001) and overall survival (OS; P <.009). Univariate and multivariate analyses indicate that KLK15 is an independent prognostic factor for PFS and OS. A weak positive correlation was found between KLK15 expression and serum CA-125 levels. CONCLUSION: KLK15 expression, as assessed by quantitative RT-PCR, is an independent marker of unfavorable prognosis for ovarian cancer. SN - 0732-183X UR - https://www.unboundmedicine.com/medline/citation/12915603/Prognostic_value_of_the_human_kallikrein_gene_15_expression_in_ovarian_cancer_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2003.09.111?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -